References

Duran C, Baumeister A. Recognition, diagnosis, and treatment of hidradenitis suppurativa. JAAPA. 2019; 32:(10)36-42 https://doi.org/10.1097/01.JAA.0000578768.62051.13

Seyed Jafari SM, Hunger RE, Schlapbach C. Hidradenitis suppurativa: current understanding of pathogenic mechanisms and suggestion for treatment algorithm. Front Med (Lausanne). 2020; 7 https://doi.org/10.3389/fmed.2020.00068

Nisar S, Roberson JL, Carney BC Further histological and cellular characterization of hidradenitis suppurativa in 11 patients. Eplasty. 2019; 19

Riis PT, Soeby K, Saunte DM, Jemec GB. Patients with hidradenitis suppurativa carry a higher systemic inflammatory load than other dermatological patients. Arch Dermatol Res. 2015; 307:(10)885-889 https://doi.org/10.1007/s00403-015-1596-5

Mehdizadeh A, Hazen PG, Bechara FG Recurrence of hidradenitis suppurativa after surgical management: a systematic review and meta-analysis. J Am Acad Dermatol. 2015; 73:(5)S70-S77 https://doi.org/10.1016/j.jaad.2015.07.044

Saunte DML, Jemec GBE. Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA. 2017; 318:(20)2019-2032 https://doi.org/10.1001/jama.2017.16691

Scuderi N, Monfrecola A, Dessy LA Medical and surgical treatment of hidradenitis suppurativa: a review. Skin Appendage Disord. 2017; 3:(2)95-110 https://doi.org/10.1159/000462979

Bouazzi D, Chafranska L, Saunte DML, Jemec GBE. Systematic review of complications and recurrences after surgical interventions in hidradenitis suppurativa. Dermatol Surg. 2020; 46:(7)914-921 https://doi.org/10.1097/DSS.0000000000002323

Ovadja ZN, Jacobs W, Zugaj M, van der Horst C, Lapid O. Recurrence rates following excision of hidradenitis suppurativa: a systematic review and meta-analysis. Dermatol Surg. 2020; 46:(8)e1-e7 https://doi.org/10.1097/DSS.0000000000002403

Bohn GA, Gass K. Leg ulcer treatment outcomes with new ovine collagen extracellular matrix dressing: a retrospective case series. Adv Skin Wound Care. 2014; 27:(10)448-454 https://doi.org/10.1097/01.ASW.0000453728.12032.6f

Lullove EJ. Use of ovinebased collagen extracellular matrix and gentian violet/methylene blue antibacterial foam dressings to help improve clinical outcomes in lower extremity wounds: a retrospective cohort study. Wounds. 2017; 29:(4)107-114

Simcock JW, Than M, Ward BR, May BC. Treatment of ulcerated necrobiosis lipoidica with ovine forestomach matrix. J Wound Care. 2013; 22:(7)383-384 https://doi.org/10.12968/jowc.2013.22.7.383

Ferzoco SJ. Early experience outcome of a reinforced bioscaffold in inguinal hernia repair: a case series. Int J Surg Open. 2018; 12:9-11 https://doi.org/10.1016/j.ijso.2018.06.001

Floden EW, Malak SF, Basil-Jones MM Biophysical characterization of ovine forestomach extracellular matrix biomaterials. J Biomed Mater Res B Appl Biomater. 2011; 96:(1)67-75 https://doi.org/10.1002/jbm.b.31740

Street M, Thambyah A, Dray M Augmentation with an ovine forestomach matrix scaffold improves histological outcomes of rotator cuff repair in a rat model. J Orthop Surg Res. 2015; 10 https://doi.org/10.1186/s13018-015-0303-8

Negron L, Lun S, May BCH. Ovine forestomach matrix biomaterial is a broad spectrum inhibitor of matrix metalloproteinases and neutrophil elastase. Int Wound J. 2014; 11:(4)392-397 https://doi.org/10.1111/j.1742-481X.2012.01106.x

Dempsey SG, Miller CH, Schueler J A novel chemotactic factor derived from the extracellular matrix protein decorin recruits mesenchymal stromal cells in vitro and in vivo. PLoS One. 2020; 15:(7) https://doi.org/10.1371/journal.pone.0235784

Irvine SM, Cayzer J, Todd EM Quantification of in vitro and in vivo angiogenesis stimulated by ovine forestomach matrix biomaterial. Biomaterials. 2011; 32:(27)6351-6361 https://doi.org/10.1016/j.biomaterials.2011.05.040

Vilanova I, Hernandez JL, Mata C Insulin resistance in hidradenitis suppurativa: a case–control study. J Eur Acad Dermatol Venereol. 2018; 32:(5)820-824 https://doi.org/10.1111/jdv.14894

Sabat R, Jemec GBE, Matusiak L, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020; 6:(1) https://doi.org/10.1038/s41572-020-0149-1

Lun S, Irvine SM, Johnson KD A functional extracellular matrix biomaterial derived from ovine forestomach. Biomaterials. 2010; 31:(16)4517-4529 https://doi.org/10.1016/j.biomaterials.2010.02.025

Bohn GA, Schultz GS, Liden BA Proactive and early aggressive wound management: a shift in strategy developed by a consensus panel examining the current science, prevention, and management of acute and chronic wounds. Wounds. 2017; 29:(11)S37-S42

Badylak SF, Valentin JE, Ravindra AK Macrophage phenotype as a determinant of biologic scaffold remodeling. Tissue Eng Part A. 2008; 14:(11)1835-1842 https://doi.org/10.1089/ten.tea.2007.0264

Overbeck N, Nagvajara GM, Ferzoco S In-vivo evaluation of a reinforced ovine biologic: a comparative study to available hernia mesh repair materials. Hernia. 2020; https://doi.org/10.1007/s10029-019-02119-z

Iida N, Fukushima K, Kanzaki A. A two-stage technique using a bovine dermal substitute to treat axillary hidradenitis. Eur J Plast Surg. 2005; 28:359-363 https://doi.org/10.1007/s00238-005-0784-5

Gonzaga TA, Endorf FW, Mohr WJ, Ahrenholz DH. Novel surgical approach for axillary hidradenitis suppurativa using a bilayer dermal regeneration template: a retrospective case study. J Burn Care Res. 2013; 34:(1)51-57 https://doi.org/10.1097/BCR.0b013e31826a7be7

Yamashita Y, Hashimoto I, Matsuo S Two-stage surgery for hidradenitis suppurativa: staged artificial dermis and skin grafting. Dermatol Surg. 2014; 40:(2)110-115 https://doi.org/10.1111/dsu.12400

Nicoli F, Balzani A, Lazzeri D Severe hidradenitis suppurativa treatment using platelet-rich plasma gel and Hyalomatrix. Int Wound J. 2015; 12:(3)338-343 https://doi.org/10.1111/iwj.12117

Tzellos T, Zouboulis CC. Review of comorbidities of hidradenitis suppurativa: implications for daily clinical practice. Dermatol Ther (Heidelb). 2020; 10:(1)63-71 https://doi.org/10.1007/s13555-020-00354-2

Extracellular matrix graft for the surgical management of hurley stage iii hidradenitis suppurativa: a pilot case series

02 July 2021
Volume 5 · Issue 3

Abstract

Objective:

Surgical management of Hurley stage III hidradenitis suppurativa (HS) typically involves the excision of diseased tissue and subsequent reconstruction, potentially leading to complications or recurrence of the disease. This pilot case series sought to evaluate a decellularised ovine forestomach matrix (OFM) extracellular matrix (ECM) graft for soft tissue regeneration as part of surgical reconstruction of stage III HS of the axilla.

Method:

The prospective pilot case series involved six participants and a total of eight defects. The ECM graft was used either as a dermal substitute for a staged reconstruction (n=3 defects) or as an implant under a fasciocutaneous flap (n=5 defects) following wide excision of the diseased tissue. Results: In all cases complete healing was achieved, with no major surgical complications. When used as a dermal substitute the OFM graft was completely granulated within 2–4 weeks, with defects closing by secondary intention or following placement of a split-thickness skin graft. When used as an implant beneath a fasciocutaneous flap, healing of the surgical sites was observed after 1–3 months. At the long-term follow-up (3–12 months), all participants had excellent range of motion and none had reported disease recurrences.

Conclusion:

This pilot case series explored the implementation of an ECM graft as part of the surgical management of axilla Hurley stage III HS. Although the study had a limited number of participants, long-term outcomes were promising and suggest further studies are warranted.

Hidradenitis suppurativa (HS) is a debilitating, chronic inflammatory disease of the dermis.1 The causes of HS may be a combination of genetic, endocrine, environmental and microbial factors.2 Disease progression involves follicular occlusion caused by inflammation, hyperkeratosis and hyperplasia of sweat glands, and can lead to multiple abscesses and cysts in the affected area.2 Histological changes in HS versus normal tissue include a thickening of the epidermis, high cellular infiltration around hair follicles and disorganised collagen fibres with a decrease in collagen III.3 Overall, systemic inflammatory markers are higher in HS than non-HS dermal diseases, such as psoriasis.4

Treatment of HS depends on disease severity (i.e., Hurley stage I, II and III) and includes medical treatments (for example, antibiotics, steroids and anti-inflammatories), as well as surgical interventions to remove the diseased tissue.2 Recurrence is lower when therapeutic and surgical approaches are combined, compared with surgery alone.5 Surgical intervention for HS depends on the severity of the disease. In mild cases, local excision or deroofing of abscesses and sinuses may be sufficient.6 In severe cases of HS (for example, Hurley stage III) that include diffuse interconnecting tracts and abscesses across a large area, a significant surgical intervention is required, such as wide excision of the diseased tissue.6 Following wide excision, several reconstructive approaches are possible, including primary closure, healing via secondary intention, split-thickness skin grafting, local and free flaps.7 Recurrence rates after a wide excision appear lower than after local excision;5 however, the extent of tissue removal means that healing time is longer and complications more likely. Bouazzi et al.8 found that complication rates and recurrence rates remain relatively high at 25.1% and 14.0%, respectively. Ovadja et al.9 estimated recurrence rates for wide and partial excisions at 5% and 26%, respectively, from a meta-analysis of 125 articles. Complications associated with reconstruction after wide excision may be attributed to the poor quality of the underlying tissues (for example, fibrotic or inflamed tissue), potential for dead space between the advancing flap and underlying tissues, poor vascularity of the tissues, and associated patient comorbidities.

Register now to continue reading

Thank you for visiting Wound Central and reading some of our peer-reviewed resources for wound care professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Access to clinical or professional articles

  • New content and clinical updates each month